Adaptive Biotechnologies (NASDAQ:ADPT) Shares Down 9.9% – Here’s What Happened

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) traded down 9.9% during mid-day trading on Thursday . The company traded as low as $12.86 and last traded at $12.8130. 778,966 shares were traded during mid-day trading, a decline of 59% from the average session volume of 1,898,585 shares. The stock had previously closed at $14.22.

Adaptive Biotechnologies News Summary

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Recent fundamental backdrop: Adaptive’s Feb. 5 quarterly report showed an EPS beat and revenue that was up ~51% year-over-year, supporting investor confidence heading into March. MarketBeat ADPT profile
• Neutral Sentiment: Short-interest print for March shows 0 shares and NaN changes (likely a reporting error). That data point provides no clear bearish signal and may have contributed to lower perceived short pressure. (No reliable short-interest signal.)
• Negative Sentiment: Significant insider selling on Mar. 11–13: combined, company executives and insiders sold roughly 1.25M shares for about $16.6M in proceeds, materially reducing several insiders’ stakes (examples below). This coordinated selling can be perceived negatively by investors as supply into the market or insiders taking liquidity. Filings: CEO Chad M. Robins (470,167 sh, ~$6.19M) Chad Robins Form 4; Harlan S. Robins (470,266 sh, ~$6.19M) Harlan Robins Form 4; COO Julie Rubinstein (160,643 sh across filings) Julie Rubinstein Form 4; CFO Kyle Piskel (18,672 sh) Kyle Piskel Form 4; Sharon Benzeno (63,103 sh) Sharon Benzeno Form 4; Susan Bobulsky (41,338 sh) Susan Bobulsky Form 4; Francis Lo (30,593 sh) Francis Lo Form 4.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a research note on Friday, February 6th. BTIG Research boosted their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. upped their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Adaptive Biotechnologies Stock Performance

The firm has a market capitalization of $2.03 billion, a P/E ratio of -32.92 and a beta of 2.19. The business has a fifty day moving average of $16.55 and a 200-day moving average of $15.85.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. During the same quarter in the previous year, the business earned ($0.23) EPS. The firm’s revenue for the quarter was up 51.0% on a year-over-year basis. On average, equities research analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Adaptive Biotechnologies

In related news, COO Julie Rubinstein sold 19,060 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $12.96, for a total value of $247,017.60. Following the completion of the sale, the chief operating officer owned 507,934 shares of the company’s stock, valued at $6,582,824.64. This represents a 3.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Susan Bobulsky sold 41,338 shares of the company’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total transaction of $544,421.46. Following the completion of the sale, the insider directly owned 427,775 shares of the company’s stock, valued at $5,633,796.75. The trade was a 8.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 2,464,588 shares of company stock valued at $36,222,545. 6.40% of the stock is currently owned by insiders.

Institutional Trading of Adaptive Biotechnologies

A number of institutional investors have recently made changes to their positions in the stock. Westfield Capital Management Co. LP acquired a new stake in Adaptive Biotechnologies in the fourth quarter worth approximately $65,942,000. Price T Rowe Associates Inc. MD increased its position in shares of Adaptive Biotechnologies by 303.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after purchasing an additional 3,299,635 shares during the period. Ameriprise Financial Inc. raised its stake in shares of Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after buying an additional 2,731,648 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Adaptive Biotechnologies by 248.8% in the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock valued at $50,468,000 after buying an additional 2,216,595 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of Adaptive Biotechnologies by 544.0% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after buying an additional 2,062,282 shares during the period. 99.17% of the stock is owned by institutional investors and hedge funds.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.